{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T12:25:34Z","timestamp":1754396734355,"version":"3.37.3"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T00:00:00Z","timestamp":1579478400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T00:00:00Z","timestamp":1579478400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the Japan Agency for Medical Research and Development via Center for Clinical Trials Japan Medical Association","award":["CCT-B-2703"],"award-info":[{"award-number":["CCT-B-2703"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s12185-020-02820-1","type":"journal-article","created":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T12:02:45Z","timestamp":1579521765000},"page":"711-718","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Phase I study of brentuximab vedotin (SGN-35) in Japanese children with relapsed or refractory CD30-positive Hodgkin\u2019s lymphoma or systemic anaplastic large cell lymphoma"],"prefix":"10.1007","volume":"111","author":[{"given":"Yuhki","family":"Koga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Sekimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Iguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Kada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko M.","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuta","family":"Asada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9180-3196","authenticated-orcid":false,"given":"Tetsuya","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keizo","family":"Horibe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,20]]},"reference":[{"key":"2820_CR1","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1200\/JCO.2004.02.121","volume":"22","author":"YE Lieskovsky","year":"2004","unstructured":"Lieskovsky YE, Donaldson SS, Torres MA, Wong RM, Amylon MD, Link MP, et al. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin\u2019s disease: results and prognostic indices. J Clin Oncol. 2004;22:4532\u201340.","journal-title":"J Clin Oncol"},{"key":"2820_CR2","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1038\/bmt.2008.111","volume":"42","author":"S Akhtar","year":"2008","unstructured":"Akhtar S, Abdelsalam M, El Weshi A, Al Husseini H, Janabi I, Rahal M, et al. High-dose chemotherapy and autologous stem cell transplantation for Hodgkin\u2019s lymphoma in the kingdom of Saudi Arabia: King Faisal specialist hospital and research center experience. Bone Marrow Transpl. 2008;42:S37\u201340.","journal-title":"Bone Marrow Transpl"},{"key":"2820_CR3","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1200\/JCO.2008.18.1487","volume":"27","author":"L Brugi\u00e8res","year":"2009","unstructured":"Brugi\u00e8res L, Le Deley M-C, Rosolen A, Williams D, Horibe K, Wrobel G, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL group. J Clin Oncol. 2009;27:897\u2013903.","journal-title":"J Clin Oncol"},{"key":"2820_CR4","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/j.1365-2141.2005.05910.x","volume":"132","author":"T Mori","year":"2006","unstructured":"Mori T, Takimoto T, Katano N, Kikuchi A, Tabuchi K, Kobayashi R, et al. Recurrent childhood anaplastic large cell lymphoma: a retrospective analysis of registered cases in Japan. Br J Haematol. 2006;132:594\u20137.","journal-title":"Br J Haematol"},{"key":"2820_CR5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/j.1365-2141.2006.06004.x","volume":"133","author":"W Woessmann","year":"2006","unstructured":"Woessmann W, Peters C, Lenhard M, Burkhardt B, Sykora K-W, Dilloo D, et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents\u2014a Berlin\u2013Frankfurt\u2013Munster group report. Br J Haematol. 2006;133:176\u201382.","journal-title":"Br J Haematol"},{"key":"2820_CR6","doi-asserted-by":"publisher","first-page":"5056","DOI":"10.1200\/JCO.2008.20.1764","volume":"27","author":"L Brugieres","year":"2009","unstructured":"Brugieres L, Pacquement H, Le Deley M-C, Leverger G, Lutz P, Paillard C, et al. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. J Clin Oncol. 2009;27:5056\u201361.","journal-title":"J Clin Oncol"},{"key":"2820_CR7","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363:1812\u201321.","journal-title":"N Engl J Med"},{"key":"2820_CR8","unstructured":"Study of brentuximab vedotin (SGN-35) in Pediatric participants with relapsed or refractory (r\/r) systemic anaplastic large-cell lymphoma or hodgkin lymphoma. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01492088 (2019). Accessed 24 July 2019."},{"key":"2820_CR9","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","volume":"30","author":"B Pro","year":"2012","unstructured":"Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30:2190\u20136.","journal-title":"J Clin Oncol."},{"key":"2820_CR10","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/cas.12435","volume":"105","author":"M Ogura","year":"2014","unstructured":"Ogura M, Tobinai K, Hatake K, Ishizawa K, Uike N, Uchida T, et al. Phase I\/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin\u2019s lymphoma or systemic anaplastic large-cell lymphoma. Cancer Sci. 2014;105:840\u20136.","journal-title":"Cancer Sci"},{"key":"2820_CR11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12885-018-4042-1","volume":"18","author":"M Sekimizu","year":"2018","unstructured":"Sekimizu M, Iguchi A, Mori T, Koga Y, Kada A, Saito AM, et al. Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin\u2019s lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol. BMC Cancer. 2018;18:122.","journal-title":"BMC Cancer"},{"key":"2820_CR12","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1016\/S2352-3026(18)30153-4","volume":"5","author":"F Locatelli","year":"2018","unstructured":"Locatelli F, Mauz-Koerholz C, Neville K, Llort A, Beishuizen A, Daw S, et al. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin\u2019s lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1\/2 study. Lancet Haematol. 2018;5:e450\u201361.","journal-title":"Lancet Haematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-02820-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-020-02820-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-02820-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:34:51Z","timestamp":1611016491000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-020-02820-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,20]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["2820"],"URL":"https:\/\/doi.org\/10.1007\/s12185-020-02820-1","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2020,1,20]]},"assertion":[{"value":"22 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"YK, AI, and TM reports grants from Japan Agency for Medical Research and Development via Center for Clinical Trials Japan Medical Association, during the conduct of the study. MS reports grants from Japan Agency for Medical Research and Development via Center for Clinical Trials Japan Medical Association, during the conduct of the study; non-financial support from Pfizer Japan Inc., outside the submitted work. AK reports personal fees from Bayer Yakuhin, Ltd. as a member of an independent data monitoring committee of clinical trials, outside the submitted work. KH reports personal fees from Chugai Pharmaceutical Co., Ltd., Amgen Astellas BioPharma K.K., and Sumitomo Dainippon Pharma Co., Ltd, grants and non-financial support from Pfizer Japan Inc., outside the submitted work. The other authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}